Clinical Trials Logo

Egg Hypersensitivity clinical trials

View clinical trials related to Egg Hypersensitivity.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06273605 Recruiting - Food Allergy Clinical Trials

The Egg Up Trial - Testing a New Treatment Pathway for Infants With Newly Diagnosed Egg Allergy

Start date: April 9, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to test the safety and feasibility of a change in management approach for infants with newly diagnosed egg allergy. Infants with newly diagnosed egg allergy will have egg introduced via a gradual and graded home based approach known as an "egg ladder" supervised by a dietitian. The main questions this study aims to answer are how safe and feasible are home-based dietitian-led "egg ladders" as a treatment pathway to achieve tolerance of egg for newly diagnosed infants with egg allergy.

NCT ID: NCT06256146 Recruiting - Peanut Allergy Clinical Trials

Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety

IMPROVES
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Protocols for Oral Immunotherapy (OIT) for the main food allergens have been recently incorporated in clinical practice for food allergies and their clinical benefits have been acknowledged in European and Canadian official guidelines. There has been some reluctance in both clinicians and patients to implement these therapies, primarily because of the risk of allergic reactions during the desensitization process. This study will investigate if protocols using low doses of a food allergen or processed versions of the allergen can be both effective in conferring desensitization while inducing fewer allergic symptoms during the desensitization process.

NCT ID: NCT05740163 Recruiting - Egg Allergy Clinical Trials

Oral Immunotherapy for Egg Allergy in Children Aged 6 to 16

Start date: December 30, 2019
Phase: N/A
Study type: Interventional

The aim of the study is to determine the efficacy of a 12-month egg oral immunotherapy (OIT) protocol with a cooked whole egg product including yolk and egg white. Study hypothesis: With this method the risk for severe allergic reaction to egg protein is reduced and the diet can partly or completely be normalized.

NCT ID: NCT05309772 Recruiting - Food Allergy Clinical Trials

The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy

Start date: January 13, 2023
Phase: N/A
Study type: Interventional

The BAT Impact study is a prospective multicentre study in the UK using a biomarker-led study design to compare the incidence of adverse events (defined as allergic reactions during oral food challenges) in a randomized-controlled trial. Patients will either follow the standard-of-care (i.e. an oral food challenge in case of equivocal SPT/sIgE) or follow a basophil activation test (BAT)/mast cell activation test (MAT)-based strategy, i.e. patients with a positive BAT or MAT are dispensed of an oral food challenge (OFC) and patients with a negative BAT/MAT undergo an OFC.

NCT ID: NCT03309488 Recruiting - Food Allergy Clinical Trials

Basophil Activation Test to Diagnose Food Allergy

BAT2
Start date: January 30, 2018
Phase:
Study type: Observational

The BAT II Study is a cross-sectional diagnostic study in which children with suspected IgE-mediated allergy to foods (namely cow's milk, egg, sesame and cashew), as defined by a history of an immediate-type allergic reaction to a food or no history of food consumption or the presence of food-specific IgE as documented by skin prick test or serum specific IgE, will undergo a diagnostic work-up to confirm or refute the diagnosis of IgE-mediated food allergy. Participants will be prospectively recruited from specialised Paediatric Allergy clinics in London and will undergo skin prick testing (SPT), specific IgE testing to allergen extracts and allergen components, basophil activation test (BAT) and oral food challenge. The diagnostic accuracy of the BAT and of other allergy tests will be assessed against the clinical gold-standard.